Skip to content

Compare the effects of pioglitazone with fenofibrate in treatment of patients with NAFLD

Compare the effects of pioglitazone with fenofibrate in treatment of patients with NAFLD

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015120819554N10
Enrollment
90
Registered
2016-07-12
Start date
2016-07-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic steatohepatitis. Other specified inflammatory liver diseases, Nonalcoholic steatohepatitis [NASH]

Interventions

Intervention 1: Tab pioglitazone 30 mg once a day. Intervention 2: Tab fenofibrat 200 mg once aday.
Treatment - Drugs
Tab pioglitazone 30 mg once a day
Tab fenofibrat 200 mg once aday

Sponsors

Vice Chancellor for research, Zanjan University Of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with NAFLD on ultrasonography; ALT more than 1.5 to 5 times the normal range; BMI between 25 to 29.9 Exclusion criteria: Alcoholic hepatitis; systemic or metabolic or inflammatory disease such as diabetes; viral hepatitis; autoimmune hepatitis; secondary fatty liver disease such as drug induced fatty liver disease

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
ALT. Timepoint: once at the begining and the second time after twelve weeks. Method of measurement: ELIZA.;FBS. Timepoint: once at the begining and the second time after twelve weeks. Method of measurement: ELIZA.;Lipid profile. Timepoint: once at the begining and the second time after twelve weeks. Method of measurement: ELIZA.

Secondary

MeasureTime frame
Improve fatty liver. Timepoint: once at the begining and the second time after twelve weeks. Method of measurement: Specific liver enzyme tests.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Maryam Jameshorani

Zanjan,University Of Medical Sciences

dr.shirinjameshorani@yahoo.com+98 24 3342 4766

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026